Yakymenko Dorthe, Skougaard Kristin
Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Centre for Medicines Licensing & Pharmacovigilance Oncology & Hematology, Danish Medicines Agency, Copenhagen, Denmark.
Eur Clin Respir J. 2023 Apr 3;10(1):2194162. doi: 10.1080/20018525.2023.2194162. eCollection 2023.
Lung cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs) are at risk of developing immune-related (ir-)pneumonitis. Since lung cancer patients have competing reasons for respiratory symptoms, this poses a diagnostic challenge. This study aimed to explore diagnosis and management of ir-pneumonitis in this patient group.
Suspected ir-pneumonitis was frequent in this group of patients. The cohort was characterized by high heterogeneity and lack of unequivocal diagnostic conclusions. Treatment of ir-pneumonitis was longer than recommended and involvement of pulmonologist was very infrequent. The result of this study reflects the difficulties in a daily clinical setting to diagnose and manage patients with lung cancer presenting with pulmonary symptoms.
Suspected ir-pneumonitis was frequent in this group of patients. The cohort was characterized by high heterogeneity and lack of unequivocal diagnostic conclusions. Treatment of ir-pneumonitis was longer than recommended and involvement of pulmonologist was very infrequent. The result of this study reflects the difficulties in a daily clinical setting to diagnose and manage patients with lung cancer presenting with pulmonary symptoms.
接受免疫检查点抑制剂（ICI）治疗的肺癌患者有发生免疫相关肺炎（ir-肺炎）的风险。由于肺癌患者出现呼吸道症状有多种原因，这带来了诊断挑战。本研究旨在探讨该患者群体中ir-肺炎的诊断和管理。
在这组患者中，疑似ir-肺炎很常见。该队列的特点是高度异质性且缺乏明确的诊断结论。ir-肺炎的治疗时间比推荐的更长，肺科医生的参与非常少见。本研究结果反映了在日常临床环境中诊断和管理出现肺部症状的肺癌患者的困难。
在这组患者中，疑似ir-肺炎很常见。该队列的特点是高度异质性且缺乏明确的诊断结论。ir-肺炎的治疗时间比推荐的更长，肺科医生的参与非常少见。本研究结果反映了在日常临床环境中诊断和管理出现肺部症状的肺癌患者的困难。
